Background
About 30 % of the
patients initiated on antiretroviral therapy in Zambia default treatment. Some
of these patients later restart treatment; however, the characteristics of
these patients have not been well described and documented. The aim of this study
was to describe and document the socio-demographic and clinical characteristics
of patients who default and restart antiretroviral therapy, and to determine
the socio-demographic characteristics associated with CD4 count response at 6
and 24 months of restarting antiretroviral therapy.
Methods
A longitudinal
retrospective analysis was performed on data from 535 adult patients restarting
antiretroviral therapy in 2009 and 2010 at five antiretroviral therapy centres
in Copperbelt and Central provinces of Zambia. To determine the association
between the socio-demographic characteristics and CD4 cell count, quantile
regression models were used.
Results
Older age above
45 years was associated with a significantly lower CD4 cell response by
38.1 cells/mm3 compared to the younger age (15–29 years). Patients in formal employment and
self-employment gained significantly higher
CD4 cells than those unemployed. In addition, baseline CD4 count, type of
treatment, WHO staging, total duration on treatment and duration lost to
follow-up were found to be strong predictors of CD4 cell count at 6 and
24 months after restarting antiretroviral therapy treatment.
Conclusion
Age and occupation were
the only socio-demographic characteristics predicting CD4 count in the patients
at 6 months after restarting antiretroviral therapy after adjusting for
other confounding clinical variables.
Below: Boxplots of Interquartile range of CD4 count at restarting ART, 6 and 24 months after restaring ART
Full article at: http://goo.gl/8P145h
Department of Public
Health, School of Medicine, University of Zambia, PO Box 50110, Lusaka, Zambia
FHI 360, Plot
2374, Farmers Village, ZNFU Complex, Lusaka, Zambia
BMC Public Health. 2016; 16: 289.
Published online 2016 Mar 29. doi: 10.1186/s12889-016-2922-3
More at: https://twitter.com/hiv insight
No comments:
Post a Comment